182 filings
6-K
ADXN
Addex Therapeutics Ltd
29 Apr 24
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
6:05am
424B3
ADXN
Addex Therapeutics Ltd
24 Apr 24
Prospectus supplement
4:00pm
EFFECT
ADXN
Addex Therapeutics Ltd
23 Apr 24
Notice of effectiveness
12:15am
POS AM
ADXN
Addex Therapeutics Ltd
18 Apr 24
Prospectus update (post-effective amendment)
4:00pm
20-F
2023 FY
ADXN
Addex Therapeutics Ltd
Annual report (foreign)
18 Apr 24
6:15am
6-K
ucs6t9f
18 Apr 24
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
6:05am
6-K
f478hb l66cff
3 Apr 24
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
6:05am
424B5
kaof9vcp96
30 Jan 24
Prospectus supplement for primary offering
5:00pm
6-K
2a820dx
30 Jan 24
Current report (foreign)
4:58pm
6-K/A
1sl hhnlvjftah
21 Dec 23
Current report (foreign) (amended)
6:00am
6-K
x35dev5e
20 Dec 23
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
6:05am
6-K
3wu30
14 Dec 23
Addex Creates Treasury Shares
6:05am
424B3
o3bi wx666jtn45tt
30 Nov 23
Prospectus supplement
4:00pm
EFFECT
iqblz0w4z u7lks6z
30 Nov 23
Notice of effectiveness
12:15am
POS AM
dhg9gcac
29 Nov 23
Prospectus update (post-effective amendment)
6:27am
6-K
poz9ern
29 Nov 23
Current report (foreign)
6:00am
6-K
mmivbsavqavgouz hdpj
28 Nov 23
Addex Convenes Extraordinary General Meeting
6:05am
6-K
9dwq6 uyvs
14 Nov 23
Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
6:05am
6-K
20pj3 oze5
8 Nov 23
Current report (foreign)
6:05am
424B3
01y wdep8
23 Oct 23
Prospectus supplement
6:01am